Medtronic (NYSE:MDT) said today that it inked a deal with health insurer Aetna (NYSE:AET) to measure outcomes for patients with Type 1 and Type 2 diabetes on multiple daily insulin injections.
The program is designed for patients who elect to move to an insulin pump, using a Medtronic pump with its SmartGuard tech and its MiniMed 670G system.
